Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.41 |
| ▸ | HTR2C | P28335 | 6/20 | 0.41 |
| ▸ | HTR7 | P34969 | 12/20 | 0.39 |
| ▸ | HTR1A | P08908 | 6/20 | 0.39 |
| ▸ | DRD2 | P14416 | 6/20 | 0.39 |
| ▸ | USP1 | O94782 | 1/20 | 0.37 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17306795 | 1.00 | HTR2A (0.41) | HTR2AHTR2CHTR7HTR1ADRD2 | |
| SCHEMBL17303825 | 0.84 | HTR2A (0.60) | HTR2AHTR2CNPY5R | |
| SCHEMBL15830332 | 0.84 | HTR2A (0.60) | HTR2AHTR2CNPY5R | |
| SCHEMBL17303999 | 0.84 | HTR2A (0.60) | HTR2AHTR2CNPY5R | |
| SCHEMBL17300900 | 0.82 | HTR2A (0.43) | HTR2AHTR2CHTR7HTR1ADRD2 | |
| SCHEMBL17300872 | 0.82 | HTR2A (0.43) | HTR2AHTR2CHTR7HTR1ADRD2 | |
| SCHEMBL17300886 | 0.82 | HTR2A (0.43) | HTR2AHTR2CHTR7HTR1ADRD2 | |
| SCHEMBL19287742 | 0.80 | SLC6A2 (0.39) | HTR2AHTR2CHTR7HTR1ADRD2 | |
| SCHEMBL19287840 | 0.78 | SLC6A2 (0.46) | HTR2CNPY5R | |
| SCHEMBL17303823 | 0.77 | HTR2C (0.53) | HTR2AHTR2CHTR7NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190343826-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-11-14 | — | — | US | disclosed |
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9745291-B2 | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof | Epizyme, Inc. (US) | 2017-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343826-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | HTR2A 3996/4885HTR2C 3973/4885HTR7 3240/4885 |
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT3 | HTR2A 3996/4885HTR2C 3973/4885HTR7 3240/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | HTR2A 3996/4885HTR2C 3973/4885HTR7 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.